Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Biotech
FDA delays decision on Merus' first-in-class cancer drug
The agency has pushed back the decision date by three months to give its staff more time to assess recently submitted information.
Nick Paul Taylor
Nov 5, 2024 9:14am
Roche MAGE-A4 trial withdrawn after strategic review
Oct 18, 2024 5:30am
Context builds bispecific bank with $133M biobucks deal
Sep 23, 2024 11:20am
Trispecific antibody one-ups Tecvayli in myeloma mouse study
Sep 17, 2024 3:38pm
Candid flashes big ambitions with $370M debut
Sep 9, 2024 9:00am
FDA rejects Regeneron bispecific, delaying rival to J&J, Pfizer
Aug 21, 2024 5:48am
